AsiDNA

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 – 18:00 CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the U.S. Patent and Trademark…read more →

Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), January 31, 2017 – 08:30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, and the Institut Curie, a…read more →

The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class product derived directly from this technology Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that…read more →

Onxeo Strengthens AsiDNA™ Patent Protection in Europe

Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence until 2027 Any product including this specific DNA sequence will be within the scope of this patent AsiDNA™’s intellectual property will now be protected by 8 complementary patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen:…read more →

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced results from a preclinical study demonstrating that the synergistic effect of its lead signal-interfering DNA product candidate AsiDNA™ in combination with various products in the PARP (PolyADP-Ribose Polymerase) inhibitor…read more →

Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031 // DANISH TRANSLATION: Onxeo modtager “Notice of Allowance” fra de amerikanske patentmyndigheder for det primære AsiDNA™ patent, hvilket forlænger patentbeskyttelsen i USA indtil 2031

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair signal interfering technology and products protected by 8 patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapies, today…read more →

Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA // DANISH TRANSLATION: Onxeo offentliggør udviklingsplan for det innovative signal-interfererende DNA-produkt AsiDNA

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Near- and mid term expected milestones  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), an innovative company specializing in the development of orphan oncology therapeutics, today announced its plan for further development of AsiDNA, its first-in-class signal interfering DNA molecule which breaks the cycle of tumor DNA…read more →

Onxeo announces closing of DNA Therapeutics acquisition // DANISH TRANSLATION: Onxeo gennemfører opkøbet af DNA Therapeutics

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has completed the acquisition of DNA Therapeutics and its signal-interfering DNA (siDNA) repair technology and lead product…read more →

Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan // DANISH TRANSLATION: Onxeo offentliggør opkøb af DNA Therapeutics og giver en opdatering om udviklingsplanen for Validive®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment  Acquisition expands Company’s R&D pipeline and opens new opportunities in orphan oncology indications Further development of Validive® to be conducted in partnership Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company…read more →